FASEB's "The Translational Neuroimmunology Conference: From Mechanisms to Therapeutics."
FASEB 的“转化神经免疫学会议:从机制到治疗学”。
基本信息
- 批准号:10065269
- 负责人:
- 金额:$ 0.3万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-07-01 至 2021-06-30
- 项目状态:已结题
- 来源:
- 关键词:Alzheimer&aposs DiseaseAreaBasic ScienceBehaviorCNS autoimmune diseaseCentral Nervous System DiseasesCentral Nervous System InfectionsClinicalCollaborationsCommunicationCommunitiesComplexDevelopmentDiseaseDisease ProgressionEducational workshopEnsureEnvironmentEquilibriumEthnic OriginEvaluationFosteringFundingGeneticGlioblastomaGoalsGrantHealthHealth systemHomeostasisHumanImmune responseImmune systemImmunologistImmunologyIndividualInnate Immune ResponseKnowledgeLifeMaintenanceMeningesMicrobiologyMolecularMultiple SclerosisNerve DegenerationNervous System PhysiologyNervous system structureNeuraxisNeurodegenerative DisordersNeurodevelopmental DisorderNeuroimmuneNeuroimmunomodulationNeurologyNeurosciencesOralParticipantPathogenicityPathologyPathway interactionsPostdoctoral FellowPreparationPublicationsRegulationResearchResearch PersonnelRoleSTEM fieldScienceScientistSex ChromosomesSpinal cord injuryStudentsSurveysTalentsTherapeuticTimeTissuesTranslatingTranslational ResearchWorkadaptive immune responsebasecareercombatdefined contributionimprovedmeetingsmembermicrobialmultidisciplinarynervous system disorderneuroimmunologyneuroinflammationneurological pathologynext generationpathogenpathogenic microbeposterspreventprogramsrecruitrepairedresponsesuccesssupportive environmentsymposiumtargeted treatmenttherapy developmenttoxicant
项目摘要
Abstract (30 lines max):
The purpose of this R13 submission is to request funds for trainees and for a limited number of junior
investigator speakers and those from groups traditionally underrepresented in the STEM fields to participate in
the 2020 FASEB Science Research Conference: The Translational Neuroimmunology Conference: from
mechanisms to therapeutics. This will be the 15th FASEB Neuroimmunology conference and will be held at the
Babson Executive Conference Center from July 19-23, 2020. The last FASEB meeting was held in Snowmass,
CO in 2018, where Dr. Benjamin Segal was elected as co-chair to work with Dr. Thomas Lane who was the
2018 co-chair and is the 2020 chair. The 2020 conference builds upon the excellence of previous meetings
and brings together a diverse group of neuroscientists, immunologists, clinicians, microbiologists, translational
and basic research scientists at a venue and with a program fostering interaction between individuals with
different expertise and at different career stages. Previous evaluations have ranked this conference highly for
outstanding presentations and discussion time, for high impact speakers who remain for the duration of the
conference, selection of abstracts from junior scientists and graduate trainees for short platform presentations,
well-attended poster sessions, time for free and open discussions between speakers and attendees aimed at
fostering new and ongoing collaborations. The 2020 program is aimed at defining the contributions of
neuroimmune interactions in CNS as it relates to emerging topics including understanding the role of sex
chromosomes and neuroinflammation and assessing the role of the innate immune response in
neurodegeneration. We also seek to explore the opportunities and challenges for harnessing neuroimmune
interactions as therapies for classic neurologic and neurodegenerative diseases including multiple sclerosis,
Alzheimer’s disease, spinal cord injury, glioblastoma and CNS autoimmune diseases. In response to
evaluation requests from trainees and junior investigators attending the 2018 conference, new this year are
addition of two workshops discussing pragmatic issues and careers aimed at bridging pathways from discovery
to human therapies and the role of scientific rigor in grant preparation and publication. In aggregate, the
specific goals of this conference are to: 1) provide a forum for the presentation of unpublished, cutting-edge
research by investigators from diverse fields applicable to neuroimmune regulation of CNS health and disease;
2) provide forums for both formal and informal discussions on how results from complementary fields advance
our understanding of how neuroimmune interactions support CNS function and health lifelong and can be
modified by genetics, pathogens, toxicants and behavior to drive disease pathology, and 3) ensure
development and integration of young investigators from diverse backgrounds and those traditionally under-
represented in these fields into the broader research community in a meaningful and interactive way.
Altogether, attendees will enjoy a multidisciplinary group of researchers not found together at other specialized
conferences and will benefit from the focus on the opportunities & challenges in translating research
discoveries to therapies.
摘要(最多30行):
提交R13申请的目的是为学员和数量有限的初级学员申请资金。
研究人员发言人和那些来自传统上在STEM领域代表性不足的群体的人参加,
2020年FASEB科学研究会议:转化神经免疫学会议:从
机制到治疗学。这将是第15届FASEB神经免疫学会议,将在
巴布森行政会议中心,2020年7月19日至23日。上一次FASEB会议在斯诺马斯举行,
2018年,本杰明·西格尔博士当选为共同主席,与托马斯·莱恩博士合作,后者是
2018年担任联合主席,2020年担任主席。2020年的会议建立在以往会议的卓越基础上
并汇集了一群不同的神经科学家,免疫学家,临床医生,微生物学家,翻译
和基础研究科学家在一个地点,并与一个计划,促进个人之间的互动,
不同的专业知识和不同的职业阶段。以往的评价都高度评价这次会议,
杰出的演讲和讨论时间,为高影响力的发言者谁留在会议期间,
会议,从初级科学家和研究生学员中挑选摘要,供简短的平台介绍,
出席人数众多的海报会议,发言者和与会者之间进行自由和公开讨论的时间,
促进新的和正在进行的合作。2020年计划旨在确定
CNS中的神经免疫相互作用,因为它涉及到新出现的主题,包括了解性别的作用
染色体和神经炎症,并评估先天免疫反应在
神经变性我们还寻求探索利用神经免疫的机会和挑战,
相互作用作为经典神经和神经变性疾病包括多发性硬化症的疗法,
阿尔茨海默病、脊髓损伤、胶质母细胞瘤和CNS自身免疫性疾病。响应于
参加2018年会议的受训人员和初级研究人员的评估请求,今年是新的,
增加了两个研讨会,讨论务实的问题和职业,旨在弥合从发现到发现的道路
人类疗法以及科学严谨性在资助准备和出版中的作用。总体而言,
本次会议的具体目标是:1)提供一个论坛,介绍未出版的,尖端的
来自不同领域的研究人员的研究适用于中枢神经系统健康和疾病的神经免疫调节;
2)为正式和非正式讨论提供论坛,讨论如何推进互补领域的成果
我们对神经免疫相互作用如何支持CNS功能和终身健康的理解,
由遗传、病原体、毒物和行为改变以驱动疾病病理,以及3)确保
发展和整合来自不同背景的年轻调查人员和传统上在
以有意义和互动的方式将这些领域的代表纳入更广泛的研究社区。
总之,与会者将享受一个多学科的研究人员小组没有发现在一起,在其他专业
会议,并将受益于对翻译研究的机遇和挑战的关注
从发现到治疗
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Thomas E Lane其他文献
Thomas E Lane的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Thomas E Lane', 18)}}的其他基金
Defining mechanisms of disease and repair in a viral model of multiple sclerosis
定义多发性硬化症病毒模型中的疾病和修复机制
- 批准号:
10640816 - 财政年份:2020
- 资助金额:
$ 0.3万 - 项目类别:
Chemokines and Viral-Induced Neurologic Disease
趋化因子和病毒引起的神经系统疾病
- 批准号:
10090528 - 财政年份:2020
- 资助金额:
$ 0.3万 - 项目类别:
Human neural precursor cell-mediated therapy in a viral model of demyelination
脱髓鞘病毒模型中的人神经前体细胞介导的治疗
- 批准号:
10076583 - 财政年份:2020
- 资助金额:
$ 0.3万 - 项目类别:
Human neural precursor cell-mediated therapy in a viral model of demyelination
脱髓鞘病毒模型中的人神经前体细胞介导的治疗
- 批准号:
8874463 - 财政年份:2015
- 资助金额:
$ 0.3万 - 项目类别:
Viral-induced demyelination and neural stem cell-mediated remyelination
病毒诱导的脱髓鞘和神经干细胞介导的髓鞘再生
- 批准号:
8885924 - 财政年份:2011
- 资助金额:
$ 0.3万 - 项目类别:
Viral-induced demyelination and neural stem cell-mediated remyelination
病毒诱导的脱髓鞘和神经干细胞介导的髓鞘再生
- 批准号:
8799481 - 财政年份:2011
- 资助金额:
$ 0.3万 - 项目类别:
Viral-induced demyelination and neural stem cell-mediated remyelination
病毒诱导的脱髓鞘和神经干细胞介导的髓鞘再生
- 批准号:
8291218 - 财政年份:2011
- 资助金额:
$ 0.3万 - 项目类别:
Viral-induced demyelination and neural stem cell-mediated remyelination
病毒诱导的脱髓鞘和神经干细胞介导的髓鞘再生
- 批准号:
8490463 - 财政年份:2011
- 资助金额:
$ 0.3万 - 项目类别:
Viral-induced demyelination and neural stem cell-mediated remyelination
病毒诱导的脱髓鞘和神经干细胞介导的髓鞘再生
- 批准号:
8152289 - 财政年份:2011
- 资助金额:
$ 0.3万 - 项目类别:
Chemokine IP-10 and Viral-Induced Demyelination
趋化因子 IP-10 和病毒引起的脱髓鞘
- 批准号:
6657924 - 财政年份:2003
- 资助金额:
$ 0.3万 - 项目类别:
相似国自然基金
新型F-18标记香豆素衍生物PET探针的研制及靶向Alzheimer's Disease 斑块显像研究
- 批准号:81000622
- 批准年份:2010
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
阿尔茨海默病(Alzheimer's disease,AD)动物模型构建的分子机理研究
- 批准号:31060293
- 批准年份:2010
- 资助金额:26.0 万元
- 项目类别:地区科学基金项目
跨膜转运蛋白21(TMP21)对引起阿尔茨海默病(Alzheimer'S Disease)的γ分泌酶的作用研究
- 批准号:30960334
- 批准年份:2009
- 资助金额:22.0 万元
- 项目类别:地区科学基金项目
相似海外基金
Pathophysiological mechanisms of hypoperfusion in mouse models of Alzheimer?s disease and small vessel disease
阿尔茨海默病和小血管疾病小鼠模型低灌注的病理生理机制
- 批准号:
10657993 - 财政年份:2023
- 资助金额:
$ 0.3万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10381163 - 财政年份:2022
- 资助金额:
$ 0.3万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10531959 - 财政年份:2022
- 资助金额:
$ 0.3万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10700991 - 财政年份:2022
- 资助金额:
$ 0.3万 - 项目类别:
Interneurons as early drivers of Huntington´s disease progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10518582 - 财政年份:2022
- 资助金额:
$ 0.3万 - 项目类别:
Interneurons as Early Drivers of Huntington´s Disease Progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10672973 - 财政年份:2022
- 资助金额:
$ 0.3万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10585925 - 财政年份:2022
- 资助金额:
$ 0.3万 - 项目类别:
Oligodendrocyte heterogeneity in Alzheimer' s disease
阿尔茨海默病中的少突胶质细胞异质性
- 批准号:
10180000 - 财政年份:2021
- 资助金额:
$ 0.3万 - 项目类别:
Serum proteome analysis of Alzheimer´s disease in a population-based longitudinal cohort study - the AGES Reykjavik study
基于人群的纵向队列研究中阿尔茨海默病的血清蛋白质组分析 - AGES 雷克雅未克研究
- 批准号:
10049426 - 财政年份:2021
- 资助金额:
$ 0.3万 - 项目类别:
Repurposing drugs for Alzheimer´s disease using a reverse translational approach
使用逆翻译方法重新利用治疗阿尔茨海默病的药物
- 批准号:
10295809 - 财政年份:2021
- 资助金额:
$ 0.3万 - 项目类别: